LLY - Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value
2024-01-31 13:25:01 ET
Summary
- I forecast GLP-1 drugs to become the largest-selling pharmaceutical class, with US sales of $150 billion in 2030.
- GLP-1 agonists have shown favorable cardiovascular outcomes and beneficial effects on various organs, and in 2024 there will be data on Lilly's tirzepatide in NASH, sleep apnea and cardiovascular disease.
- Eli Lilly's upcoming earnings report and 2024 guidance, on February 6, will focus on Mounjaro and ZepBound, with potential for upward revenue revisions and stock performance.
As I have written regarding Eli Lilly and Company ( LLY ) beginning in August 2023 , I expect the GLP-1 drugs to become the largest sell pharmaceutical class ever, with US sales of $150 billion in 2030. I recently listened to a Grand Rounds presentation on the GLP-1s given at a major medical center . I shall discuss the key comments, which I found to be very useful in understanding both the history of incretins as well as the multi-faceted benefits of this revolutionary drug class....
Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value